Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Women TAF-FTC Benchmark Study
PACTR202209528604242Phase 2Not yet recruiting
- Sponsor
- University of Washington
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tenofovir alafenamide and emtricitabine in human immunodeficiency virus infection (HIV), sponsored by University of Washington. Primary endpoints: Safety and emergent HIV infection, Dose effect on steady-state TFV-DP concentrations and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
tenofovir alafenamideemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202209528604242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202209528604242.